 |
5 Diseases |  |
3 Trials |
|
3 Trials |  |
10 News |  |
- | Insuman Basal (isophane insulin) / Sanofi
Seems to be the same as Insuman Basal in the South West too? (Twitter) - Sep 30, 2022
- | Apidra (insulin glulisine) / Sanofi
Trial completion: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 12, 2017
P1, N=44, Completed, Sponsor: Sanofi
Recruiting --> Completed
- Apidra (insulin glulisine) / Sanofi
Enrollment open, Trial initiation date: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 1, 2017
P1, N=44, Recruiting, Sponsor: Sanofi
Recruiting --> Completed Suspended --> Recruiting | Initiation date: Sep 2016 --> Feb 2017
- || New P3 trial: The SUGAR-DIP trial: Oral medication versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie versus insuline voor zwangerschapsdiabetes (EUDRACT) - Dec 21, 2016
P3, N=810, Ongoing, Sponsor: University Medical Center Utrecht
- Apidra (insulin glulisine) / Sanofi
Trial suspension, Trial primary completion date: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 3, 2016
P1, N=44, Suspended, Sponsor: Sanofi
Suspended --> Recruiting | Initiation date: Sep 2016 --> Feb 2017 Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> May 2017
- Apidra (insulin glulisine) / Sanofi
Enrollment open: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 21, 2016
P1, N=44, Recruiting, Sponsor: Sanofi
Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> May 2017 Not yet recruiting --> Recruiting
- | Apidra (insulin glulisine) / Sanofi
New P1 trial: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 22, 2016
P1, N=44, Not yet recruiting, Sponsor: Sanofi
- |||| Insuman Rapid (recombinant human insulin) / Sanofi, Insuman Comb 25 (biphasic isophane insulin suspension consisting of 25% dissolved insulin and 75% crystalline protamine insulin) / Sanofi, Insuman Basal (isophane insulin) / Sanofi
Trial completion: Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jun 11, 2013
P4, N=558, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Insuman Rapid (recombinant human insulin) / Sanofi, Insuman Comb 25 (biphasic isophane insulin suspension consisting of 25% dissolved insulin and 75% crystalline protamine insulin) / Sanofi, Insuman Basal (isophane insulin) / Sanofi
New P4 trial: Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jun 26, 2012
P4, N=558, Completed, Sponsor: Sanofi
- ||||| Lantus (insulin glargine) / Sanofi
Biomarker, New P4 trial: Establishing Cardiovascular Biomarkers to Define Preferred Lantus (clinicaltrials.gov) - Dec 4, 2011
P4, N=60, Recruiting, Sponsor: ikfe-CRO GmbH